Decision Resources Research Reports

Title	Published	Price
State of the Pharmaceutical Industry, 2007 By: Decision Resources The innovator pharmaceutical industry will face many challenges in 2007. Key among them will be repairing its tarnished reputation, the growth of the generic drug industry, and the impact of the newly elected Democratic Congress. \| more...	2/16/2007	$2,250.00
Repositioning ADME Studies: A Strategy to Reduce Drug Attrition By: Decision Resources More effectively evaluating a broad range of a drug's ADME properties during the early stages of the R&D process provides an opportunity to reduce clinical failure rates. This approach can enable researchers to eliminate poor \| more...	1/26/2007	$1,112.50
Pricing and Reimbursement Issues in Psychiatry By: Decision Resources Compared with many other disease areas (e.g., cancer, immune diseases), the costs of drug therapy for psychiatric disorders are relatively modest. However, the World Health Organization forecasts that by 2020, depression—just one of a spectrum \| more...	12/21/2006	$1,112.50
2006 Industry Dynamics: Lessons to Be Learned By: Decision Resources Stunning successes and startling failures highlight 2006’s pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for \| more...	12/21/2006	$1,112.50
Toxicity Biomarkers: Promising Tools for Accelerated Drug Development By: Decision Resources Introduction In the wake of several notorious drug withdrawals caused by unsuspected toxicities, pharmaceutical companies are searching for ways to minimize the escalating risks and costs of drug development. Biomarkers of toxicity offer the \| more...	12/21/2006	$1,112.50
Toward a Biogenerics Market: The Regulatory Conundrum By: Decision Resources Introduction The sales that biologic agents command and the costs that they impose for payers combine to generate intense interest in the development of generic biologic agents, or biogenerics. However, the biogenerics market has \| more...	12/20/2006	$1,112.50
Pharmaceutical Pricing and Reimbursement in Germany By: Decision Resources Introduction At first glance, the German pharmaceutical market looks extremely attractive to drug manufacturers. However, manufacturers seeking to do business in Germany must contend with many cost-containment measures. Further, a radical new reform of \| more...	12/20/2006	$1,112.50
Could a Validated Biomarker Transform the Lupus Market? By: Decision Resources Introduction The identification of valid biomarkers for systemic lupus erythematosus (SLE) will be an important aid to companies developing drugs for SLE and may speed drug development in this market. Although no biomarkers are \| more...	12/19/2006	$1,112.50
The Billion-Dollar Question: Which Emerging Agents Have Blockbuster Potential By: Decision Resources Introduction In 2005, more than half of the $405 billion worldwide pharmaceutical market was generated from sales of more than 100 blockbuster products. From the beginning of 2006 through mid 2008, however, 19 of \| more...	12/18/2006	$1,112.50
Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease By: Decision Resources Introduction: The repositioning of agents to treat neurodegenerative disorders represents a signifi cant opportunity for companies that have products in highly competitive markets. Although the value of neurodegenerative markets is small by comparison, the \| more...	12/18/2006	$1,112.50
Outlook for the Migraine Market With Novel Approaches Limited, Triptans Dominate By: Decision Resources Introduction: The treatment of migraine is an underserved, underdiagnosed market with great growth potential. Despite the current dominance of triptan therapies, the upcoming entrance of new formulations and new applications of existing treatments, as \| more...	12/18/2006	$1,112.50
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2006 By: Decision Resources Introduction In the major pharmaceutical markets, efforts to curb drug expenditures and to improve patient access to medications were the driving forces in the third quarter of 2006. In the United States, adjustments to \| more...	12/15/2006	$1,112.50
Industry Analysis - Changing Dynamics in Worldwide Psychiatric Franchises By: Decision Resources Introduction The treatment of psychiatric diseases is hardly straightforward; patients often try many different drug regimens and combinations in order to identify an optimal course of therapy. Although the long-term goal in treating psychiatric \| more...	12/15/2006	$1,112.50
Pharmaceutical Pricing and Reimbursement in the United States By: Decision Resources Introduction One of the most attractive features of the U.S. pharmaceutical market for manufacturers is the unrivaled freedom of its pricing and reimbursement environment. However, after many years of vigorous expansion, the U.S. pharmaceutical \| more...	12/15/2006	$2,250.00
In Vitro Diagnostics Deals: Therapeutic Area Trends By: Decision Resources IVD (in vitro diagnostics) tests are essential to the practice of health care worldwide: an estimated 60-70% of medical decisions involve a diagnostic test. This report focuses on IVD industry deals of the last few \| more...	12/12/2006	$1,112.50
Atypical Antipsychotics: Life-Cycle Management and Future Trends By: Decision Resources The $15 billion antipsychotics market will be hard hit by generics of nearly all the most frequently prescribed atypicals and by a dearth of breakthrough therapies in the pipeline. Overall market decline will be signifi \| more...	12/11/2006	$1,112.50
2006 Financings: IPOs and Pharma’s Acquisitions of Private (IPO-less) Companies By: Decision Resources Private start-up life sciences companies use at least two different financing strategies: sell the whole company to a larger pharmaceutical company or sell shares of the company on a public market. While these young companies \| more...	12/8/2006	$1,112.50
Dynamics of Hatch-Waxman Generic Challenges and Impact of the Courts, the FTC, States, and Congress By: Decision Resources Multiple forces can affect the U.S. pharmaceutical market. Understanding their potential impact is critically important for effectively positioning products for market. In 2006, companies, the courts, the Federal Trade Commission, states, and Congress all struggled \| more...	12/8/2006	$1,112.50
Noninvasive Prenatal Diagnostics: How Will They Revolutionize the Industry? By: Decision Resources Prenatal diagnostics have been used since the 1960s to help determine the health of a fetus in its mother’s womb. A key use of prenatal diagnostics is found in the diagnosis of infectious disease, such \| more...	12/7/2006	$1,112.50
New Options for Treating Neurological Disease: Stem Cell Therapy By: Decision Resources Stem cell therapy development is challenged by controversy, intellectual property issues, and a high failure rate. Despite these challenges, stem cell therapy presents some of the most promising options for hard-to-treat and highly degenerative neurological \| more...	12/6/2006	$1,112.50
New Approaches to the Treatment of Non-Hodgkin's Lymphoma By: Decision Resources Non-Hodgkin’s lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of these cancers are curable, and median survival of aggressive NHLs is poor. While \| more...	12/1/2006	$1,112.50
Medicare Part D-Outlook for 2007 By: Decision Resources The Medicare Modernization Act’s most significant achievement is the introduction of Medicare Part D, a wide-ranging new outpatient prescription drug benefit. The massive increase in the number of Medicare Part D plans in 2007 demonstrates \| more...	11/30/2006	$1,112.50
Chemical Genetics in Drug Discovery By: Decision Resources In the drive to streamline the drug discovery process, biotechnology and pharmaceutical companies are harnessing chemical genetics as a tool to overcome the limitations of traditional target-based drug discovery. Although chemical genetics approaches show great \| more...	11/30/2006	$1,112.50
Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan By: Decision Resources The enormous economic and social burden of cancer continues to grow in the aging societies of Europe and Japan. National health care systems have the unenviable task of determining how best to stretch finite resources \| more...	11/30/2006	$2,250.00
Parkinson’s Disease Biomarkers: Vital Tools for Neuroprotectants By: Decision Resources Parkinson’s disease (PD) is poised to become a significant public health burden as the population ages. We expect the number of PD cases in the seven major drug markets we cover to reach nearly 3.6 \| more...	11/20/2006	$1,112.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 2